Pfizer Reports Topline Phase 2b VESPER‑3 Data; Study Met Primary Endpoint Of Statistically Significant Weight Reduction At 28 Weeks With Competitive Tolerability For Monthly Maintenance Dosing Of GLP‑1 RA PF'3944 In Adults With Obesity Or Overweig...

Pfizer Inc. -0.81%

Pfizer Inc.

PFE

28.32

-0.81%

  • VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher dosing regimens in Phase 3
  • Study met primary endpoint of statistically significant weight reduction at 28 weeks with a competitive tolerability profile
  • Weight loss continued after pre-planned switch from weekly to monthly dosing, with no plateau observed at 28 weeks
  • 10 Phase 3 trials with PF'3944 expected to advance in 2026; expansive clinical development program underway with 20+ planned and ongoing studies across diverse obesity pipeline

Pfizer Inc. (NYSE:PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist (RA) PF'3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.